EL7.AI
StocksMediumUpdated×3•Originally published 4 November 2026•Updated 5 November 2026•
1 min read

Novo Nordisk Operating Profit Jumps 27% as Company Raises Annual Outlook for Third Time

Key Facts

1Novo Nordisk shares jumped 6% following the disclosure of positive growth metrics for its Wegovy weight-loss drug.

Novo Nordisk reported an operating profit of 31.72 billion Danish kroner for the third quarter, marking a 27% increase. The company achieved adjusted sales of 79.2 billion kroner, leading management to raise its full-year outlook for the third time in 2026.

The growth was primarily fueled by the rapid adoption of Wegovy, with 247wallst.com reporting that the oral version of the drug captured 80% of new prescriptions in the United States. NVO was trading at $40.19 on November 3, 2026, as the company updated its free cash flow guidance to a range of 60 to 70 billion kroner.

Latest Updates · 2

  1. Major·

    Update: Novo Nordisk announced plans to reduce the U.S. list prices for Wegovy and Ozempic to $675 per month. The price cuts are scheduled to take effect starting in January 2027.

  2. Notable·

    Update: Novo Nordisk is preparing to launch its next-generation obesity treatment, Cagrisema, in the United States in early 2027. The drug is positioned as the successor to the company's Wegovy franchise following its significant market success.

Open on chart